Introduction
============

Chemical transmission at the synapse plays a central role in cellular communication in both the central and peripheral nervous system. This process requires the previous storage of neurotransmitters into synaptic vesicles and their subsequent release through Ca^2+^-dependent exocytosis. The released neurotransmitters interact with specific receptors on the plasma membrane of target cells, thus triggering intracellular signals. Vesicular neurotransmitter transporters (VNTs) are the proteins responsible for the storage of these compounds into synaptic vesicles, thus determining the amount of neurotransmitter available to be released by exocytosis and, therefore, are essential components of chemical transmission in the nervous system ([@B9]; [@B71]; [@B70]). Different types of transporters are known to be involved in the uptake of neurotransmitters into synaptic vesicles. These include the vesicular glutamate transporters (VGLUTs), vesicular monoamine transporters (VMATs), vesicular acetylcholine transporter (VAChT), and vesicular inhibitory amino acid transporter (VIAAT) ([@B24]; [@B25]; [@B83]). These vesicular transporters are active transport systems that mediate the accumulation of their respective neurotransmitters by means of an electrochemical proton gradient (ΔμH^+^) across the vesicular membrane, which is generated by a vacuolar H^+^-ATPase (V-ATPase) ([@B69]; [@B101]). ΔμH^+^ is composed of a proton gradient (ΔpH, lumen acidic) and the membrane potential (ΔΨ, lumen-positive). Vesicular neurotransmitter transporters use the chemical (ΔpH), electrical (ΔΨ) or both components of ΔμH^+^ as driving forces to mediate transport of neurotransmitters against their concentration gradient ([@B17]).

ATP is a relevant chemical transmitter released from neurons and non-neuronal cells. In the extracellular space, this nucleotide undergoes successive hydrolysis by ectonucleotidases and both ATP and some of its enzymatic breakdown products (ADP and adenosine) can interact with specific cell-surface purinoceptors ([@B12]). In the nervous system, purinergic signaling is involved in a great variety of either physiological or pathological processes such as mechanosensory transduction, central control of autonomic functions, glia-glia and neuronal-glial interaction, pain, trauma, ischemia or inflammation. In addition, extracellular nucleotides exert potent long-term effects in cell proliferation, growth and development ([@B11]; [@B1]; [@B13]). In spite of the relatively well-known features of the signaling cascade after ATP secretion and activation of the purinergic receptors, the mechanism by which ATP is released from cells remains less understood. There is compelling evidence for neuronal exocytotic release of ATP ([@B84]; [@B89]; [@B37]; [@B75], [@B76]; [@B95]) and studies also support a vesicular release of ATP from glial cells ([@B78]; [@B75]; [@B10]; [@B74]; [@B105]; [@B77]; [@B48]), although additional mechanisms of nucleotide release through ATP-binding cassette transporters, pannexin or connexin hemichannels, voltage-dependent anion channels or P2X7 receptors cannot be ruled out ([@B50]; [@B7]). Consistent with this, the determination of the mechanism and physiological relevance of vesicular ATP storage and its exocytotic release, that is, vesicular ATP release, appear to be critical for the full understanding of purinergic chemical transmission at the nervous system.

In the past decades, it has been recognized that ATP is a common constituent of secretory vesicles ([@B102]; [@B33]; [@B35]; [@B69]; [@B38]). The presence of an active transport mechanism that mediate nucleotide accumulation in a ΔΨ-dependent manner has been described in adrenal medulla chromaffin granules and the kinetic behavior, solute specificity and pharmacology of the nucleotide vesicular transporter have been extensively analyzed in this secretory vesicle model ([@B47]; [@B2]; [@B100]; [@B6]; [@B27], [@B30], [@B28]). When transport was assayed using a wide range of substrate concentrations, complex non-hyperbolic saturation curves were obtained. This complex dependence of transport capacity with substrate concentration was explained on the basis of a mnemonical kinetic model ([@B27], [@B30]). The mnemonic kinetic behavior of the nucleotide vesicular transporter was further corroborated by flow cytometry analysis of fluorescent nucleotide analogs incorporation into single chromaffin granules ([@B28]). Another remarkable feature of the nucleotide vesicular transporter in chromaffin granules is its low specificity ([@B2]; [@B100]; [@B6]; [@B27], [@B30]), this transporter being able to internalize a wide diversity of nucleotides such as ATP, ADP, AMP, GTP, and UTP ([Figure 1A](#F1){ref-type="fig"}), as well as the diadenosine polyphosphates (Ap~n~A), a group of dinucleotides that are also constituents of secretory vesicles ([@B85]; [@B80],[@B81],[@B82]) and can be detected in the extracellular media both under basal conditions ([@B31]) or after stimulation of the cells with depolarizing agents or secretagogues ([@B80],[@B82]). Nucleotide uptake into chromaffin granules is significantly reduced in the presence of atractyloside ([Figure 1B](#F1){ref-type="fig"}), a compound previously described as an inhibitor of the mitochondrial ADP/ATP exchanger, and the anion transport inhibitor 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS) ([@B47]; [@B2]; [@B100]; [@B6]; [@B27], [@B30]). A nucleotide vesicular transporter with strong similarities to that described in chromaffin granules can be also observed in cholinergic synaptic vesicles isolated from *Torpedo marmorata* electric organ and brain synaptic vesicles. Again, several different nucleotides can be incorporated into the vesicles through this vesicular transporter ([@B55]; [@B29]), which also exhibits a complex kinetic behavior that can be explained by means of a mnemonical model ([@B29]). As occurs in chromaffin granules, nucleotide transport into synaptic vesicles is affected by atractyloside and DIDS, although the compound that showed more effectivity to reduce ATP uptake into the vesicles was Evans blue ([Figure 1B](#F1){ref-type="fig"}; [@B29]), a dye which was previously described as a potent inhibitor of the vesicular glutamate transporter ([@B86]). However, in spite of the accumulating evidence of the presence of an active mechanism of nucleotide transport into secretory vesicles, such as synaptic vesicles and adrenal chromaffin granules, the protein responsible for the nucleotide vesicular accumulation remained unidentified for some time.

![Chemical structure of the main transport substrates **(A)** and inhibitors **(B)** of the vesicular nucleotide transporter.](fncel-13-00224-g001){#F1}

Solute carrier 17 (SLC17) type I inorganic phosphate transporters are a group of structurally related proteins that mediate the transmembrane transport of organic anions. Members of this transporter family include the three identified isoforms of the vesicular glutamate transporter VGLUT1 (*SLC17A7*), VGLUT2 (*SLC17A6*), and VGLUT3 (*SLC17A8*) ([@B83]). In 2008, *SLC17A9*, the last identified member of this family was found to encode the vesicular nucleotide transporter (VNUT). Northern blot analysis revealed that *SLC17A9* gene is expressed in several organs, being especially abundant in the brain and the adrenal gland, regions where nucleotide vesicular transport might be relevant ([@B88]). Moreover, in the adrenal gland, the SLC17A9 protein is specifically expressed in the medulla, where it is associated with chromaffin granules, as revealed by immunohistochemistry, immunoelectron microscopy and Western blot ([@B88]). These data are compatible with the hypothesis that SLC17A9 could be responsible for the granular storage of the nucleotides. The human SLC17A9 protein was expressed, purified and incorporated into liposomes and an internal positive Δψ was generated by diffusion of K^+^ into the liposomes by the addition of valinomycin, in order to supply a driving force for nucleotide uptake. As anticipated, the SLC17A9 protein actively transported ATP at the expense of Δψ but not of ΔpH. This protein carried several nucleotides with the following order of efficacy: ATP \> UTP \> GTP \> ITP, ADP \> \> AMP. Adenosine cannot be transported by the SLC17A9 protein, whereas the diadenosine polyphosphate Ap~3~A is a good transport substrate. The substrate selectivity of the SLC17A9 protein approximately matches the nucleotide content of the organelles that store ATP ([@B88]). Additionally, SLC17A9 does not transport substrates of other members of the SLC17 family such as glutamate, aspartate, or hippuric acid, which indicates that the SLC17A9 protein is a carrier that specifically recognizes a variety of nucleotides as transport substrates. SLC17A9-mediated ATP transport is inhibited by DIDS and Evans blue ([@B88]). Atractyloside is also a partial inhibitor but only when Mg^2+^ is present in the assay medium. These characteristics are similar, if not identical, to those observed for the transport of nucleotides to chromaffin granules and synaptic vesicles. Moreover, SLC17A9 protein is endogenously expressed by PC12 pheochromocytoma cells, where it is associated with secretory granules. Suppression of SLC17A9 gene expression by RNA interference (RNAi) strongly decreased vesicular storage and release of ATP from PC12 cells. Taken together, all these results demonstrate that *SLC17A9* encodes VNUT ([@B88]; [@B63]). When mouse VNUT protein was purified and reconstituted in liposomes ([@B49]) it exhibited similar functional properties to the previously characterized human orthologue ([@B88]), thus indicating that *SLC17A9* also encodes the VNUT in rodents. An additional evidence of the essential role of this protein in the vesicular storage of nucleotides is that the vesicular release of ATP is lost from neurons and neuroendocrine cells of *VNUT* knockout (*VNUT^-/-^*) mice ([@B87]; [@B57]; [@B66]; [@B63]).

VNUT Distribution in Neuronal and GLIAL Populations of the Central Nervous System
=================================================================================

Expression and Distribution of VNUT in the Brain
------------------------------------------------

The seminal work of [@B88] showed the expression of VNUT in human and mouse brain but its cellular and subcellular distribution was not known.

Allen Mouse Brain Atlas provides a comprehensive atlas of gene expression in the adult C57BL/6J mouse brain. Data were generated using automated high-throughput procedures for *in situ* hybridization and data acquisition ([@B51]), and are publicly accessible online^[1](#fn01){ref-type="fn"}^. As shown in [Figure 2](#F2){ref-type="fig"}, VNUT transcript is widely expressed throughout the adult mouse brain, with a prominent expression found in areas such as the hippocampus or the cerebellum.

![*In situ* hybridization analysis of VNUT transcript expression in a sagittal section of adult mouse brain. Inserts show magnification of the hippocampal and cerebellar areas. Scale bar: 850 μm. Image credit: Allen Mouse Brain Atlas (<http://mouse.brain-map.org/gene/show/86822>). Image is reproduced with permission of the copyright holders.](fncel-13-00224-g002){#F2}

Immunoperoxidase labeling of rat brain tissue also showed that VNUT is widely distributed throughout the brain with particular strong VNUT immunoreactivity in the cerebellum, the hippocampus and the olfactory bulb ([@B49]).

### VNUT in the Hippocampus

[Figure 3](#F3){ref-type="fig"} shows immunofluorescence images demonstrating the presence of VNUT in cultured mouse hippocampal neurons at 7 days *in vitro*.

![Vesicular nucleotide transporter is expressed by cultured hippocampal neurons. Representative immunofluorescence images showing immunostaining for VNUT (red) and the cytoskeletal protein βIII-tubulin (green) in cultured hippocampal neurons at 7 days *in vitro*. The nuclei are counterstained with DAPI (blue). Scale bar: 20 μm. Adapted from [@B58]. Images are reproduced with permission of the copyright holders.](fncel-13-00224-g003){#F3}

Vesicular nucleotide transporter immunofluorescence could be detected in the soma and neurites of cultured hippocampal neurons, which also showed VNUT-dependent ATP release, as K^+^-evoked ATP release was attenuated by RNAi-mediated knockdown of VNUT ([@B49]). The staining pattern of VNUT in the hippocampal neurons only partially overlapped with the presynaptic terminal markers synaptophysin and synaptotagmin 1, thus indicating that VNUT was located in different neuronal compartments. The analysis of the subcellular localization of VNUT in the hippocampal neuropil by immunogold labeling and electron microscopy showed that the nucleotide transporter is associated with synaptic vesicles in both excitatory and inhibitory terminals ([@B49]). Moreover, VNUT immunoreactivity can be also detected in preterminal axons, where it was mainly located to the axoplasm as opposed to near the plasma membrane, indicating that VNUT-possessing vesicles are undergoing axonal transport ([@B49]). VNUT also appears to be associated with vesicular structures in postsynaptic dendritic spines in the hippocampal formation. Although the role of the postsynaptically localized VNUT have to be clarified in further studies, authors hypothesize that postsynaptic spines can be an additional potential source of extracellular ATP, which may act as a retrograde signal, thus modulating presynaptic transmitter release ([@B49]). Immunoisolation experiments showed that some, but not all, VGLUT1-possessing synaptic vesicles also contain VNUT, thus indicating that ATP is stored only in a subpopulation of glutamatergic vesicles. Analysis of immunogold labeling in hippocampal inhibitory terminals suggested that a similar partial segregation exists between VNUT- and VGAT-possessing vesicles ([@B49]). Taken together, all these data indicate that VNUT may confer a purinergic phenotype to hippocampal neurons by establishing an exocytotically releasable vesicular pool of ATP. Hippocampal neurons from *VNUT^-/-^* mice completely loss their capacity to release ATP in response to K^+^ stimulation ([@B87]), which is an additional confirmation of the essential role of VNUT in the neuronal vesicular storage and vesicular release of ATP in the hippocampus.

### VNUT in the Cerebellum

When localization of VNUT was analyzed by immunoperoxidase labeling in the rat brain, particularly strong immunoreactivity was observed in the cerebellar cortex. VNUT immunolabeling was detected in the somatodendritic extent of Purkinje cells, being also relevant throughout the molecular layer ([@B49]).

Further studies have shown that cultured cerebellar granule neurons express a functional VNUT that participates in the exocytotic release of ATP from these cells ([@B60]). VNUT can be detected by western blotting and immunofluorescence in the cultured granule neurons, which release ATP in a Ca^2+^-dependent manner, as stimulation of the cells with the calcium-selective ionophore ionomycin induces a significant increase of extracellular ATP ([@B60]). Exocytosis of ATP-containing vesicles can be visualized by fluorescence microscopy using quinacrine. This acidophilic antimalarial drug interacts with ATP stored in vesicles and has been extensively used as a fluorescent marker of intracellular ATP storage sites ([@B72]; [@B54]). When granule cells were loaded with quinacrine, a punctate staining was observed, which appeared not only throughout the soma but was also evident in cell prolongations, thus indicating the presence of numerous ATP enriched vesicles in the granule neurons. Depolarization of the cells with K^+^ reduced quinacrine-associated fluorescence in granule cells, showing that they release ATP via Ca^2+^-dependent exocytosis ([@B60]). Ionomicin-induced ATP release was reduced when granule neurons were treated with the VNUT inhibitor Evans blue, thus indicating the involvement of VNUT in the vesicular storage and release of ATP. Moreover, immunofluorescence assays showed the co-localization of the vesicular protein synaptophysin and VNUT immunostaining in granule neurons, which further supports the exocytotic nature of ATP release ([@B60]). However, co-localization of VNUT and the synaptic vesicle marker was incomplete, suggesting that VNUT may be also present in another type of storage vesicles or subcellular structures. The subcellular distribution of VNUT in cerebellar granule neurons was analyzed by the use of specific axonal and somatodendritic markers, such as the pan-axonal neurofilament marker SMI 312 and the microtubule-associated protein 2 (MAP2), respectively. VNUT showed co-localization with both subcellular markers, suggesting that this transporter exists both pre- and post-synaptically in the granule cells. The presence of VNUT in postsynaptic domains was confirmed by the clear co-localization of the transporter protein with the postsynaptic density protein 95 (PSD95). Interestingly, the co-localization of VNUT and the lysosomal marker LAMP-1 in certain cytosolic areas indicated that VNUT can be also found in lysosomes ([@B60]).

The glutamatergic phenotype of cerebellar granule neurons requires the vesicular storage of glutamate through VGLUTs, of which the most abundant isoform is VGLUT1. Immunofluoresecence assays showed a weak co-localization between VNUT and VGLUT1 in the granule neurons, suggesting that ATP- and glutamate-containing vesicle pools are segregated in these cells ([@B60]). Nevertheless, it should be taken into account that these studies were performed *in vitro*, in cultured granule cells. To assess whether such distribution also reflects the situation *in vivo*, slices of mouse cerebellum were immunolabeled with antibodies to VNUT and VLGUT1. These two vesicular transporters clearly showed a non-overlapping distribution with only a few examples of co-localization between VGLUT and VNUT in both the molecular or granular layers, which was consistent with the results obtained in cultured cells ([@B60]).

Cerebellar sections of P5 and P15 mice were used to analyze the distribution of VNUT during the postnatal development of the cerebellar cortex. At P5 stage, cortical layers of the cerebellum are not well defined and immature granule neurons are still migrating from the external to the internal granular layer, where they reach their final location. At this stage, VNUT was abundantly expressed and can be found in granule cell precursors and immature neurons that have not completely differentiated ([@B60]), suggesting a possible role of this transporter in the initial stages of granule cells maturation. Committed granule cells become mature neurons during the subsequent development of the cerebellum. Consistent with this, markers of neuronal progenitors and immature neurons are dramatically reduced at P15 stage. Nevertheless, VNUT expression persisted at this stage ([@B60]), indicating the relevance of VNUT during the commitment and differentiation of granule cells. These results correlate with the observations *in vitro*. VNUT expression could be detected from the first day of culture, when cerebellar granule neurons are still immature, persisting once the cells have matured and established synaptic contacts ([@B60]). Although further studies are required to fully understand the role of VNUT in the maturation of the granule cells and the development of the cerebellum, these findings, showing the localization and activity of VNUT in cerebellar granule neurons *in vitro* and their correlation with the situation *in vivo*, opens exciting new questions that need to be addressed in the future.

Double immunolabeling with antibodies against calbindin and VNUT revealed that the vesicular nucleotide transported is located adjacent to Purkinje neurons in P15 cerebellar sections, showing a filamentous morphology. Besides, co-localization between VNUT and the glial fibrillary acidic protein (GFAP) could be observed ([Figure 4A](#F4){ref-type="fig"}). This staining pattern is consistent with the presence of VNUT in Bergmann glia, a population of radial glia present in the Purkinje cell layer. Moreover, the same pattern of VNUT immunolabeling persisted in the adult stage ([Figure 4B](#F4){ref-type="fig"}), thus indicating that VNUT is present in this type of glial cells both in the advanced stages of cerebellar development and in the adult cerebellum. Bergmann glia has been postulated as one of the neurogenic populations in the cerebellum, as expression of neural stem cell markers, such as Sox2, a transcription factor that plays a key role in neurogenesis during the development of the nervous system, has been described in these cells ([@B91]; [@B3]). Presence of VNUT in these putative stem cells also supports a potential role of this vesicular transporter in the development of the cerebellum.

![Presence of VNUT in Bergmann glia. Representative immunofluorescence images showing double immunostaining for VNUT (red) and calbindin or GFAP (green) in cerebellar sections of P15 **(A)** and adult **(B)** mice. Arrowheads indicate co-localization of the immunoreactivity for VNUT and GFAP. Scale bar: 20 μm. Adapted from [@B58]. Images are reproduced with permission of the copyright holders.](fncel-13-00224-g004){#F4}

### VNUT in Midbrain Dopaminergic Neurons

Immunohistochemical studies showed the presence of VNUT in tyrosine hydroxylase (TH)-positive dopaminergic neurons of the *substantia nigra* and ventral tegmental area of the midbrain ([@B32]). All TH-positive dopaminergic neurons in these areas were VNUT-positive. Nevertheless, expression of VNUT was not restricted to dopaminergic neurons, as VNUT-positive TH-negative cells can be detected in the *substantia nigra* and other regions of the brain ([@B32]). These findings, together with the fact that VNUT is expressed by retinal dopaminergic neurons, which incorporate ATP into vesicles and release ATP when stimulated (see below), indicate that the machinery necessary for vesicular ATP release is present in dopaminergic neurons from different regions of the central nervous system, and that these dopaminergic neurons can be a source of extracellular ATP and its bioactive breakdown products ([@B32]). These purinergic ligands would mediate their actions trough purinoceptors which are pre-synaptically expressed on dopaminergic neurons and co-expressed with dopamine receptors on neurons in regions that receive the dopaminergic input ([@B4]; [@B61]). As dopaminergic neurons in the midbrain are involved in the modulation of a wide range of behaviors, such as motor control, motivation and reward responses ([@B103]; [@B39]; [@B14]), it is likely that purinergic transmission could play a role in these processes. Likewise, purinergic neurotransmission could have a role in neurological disorders involving dysregulation of midbrain dopaminergic pathways, such as Parkinson's disease ([@B19]; [@B34]).

VNUT in Glial Cells
-------------------

### VNUT in Astrocytes

Several studies have shown that astrocytes respond to neurotransmitters and release different gliotransmitters, including ATP, which can trigger propagation of Ca^2+^ waves in these cells and modulate the activity of surrounding neurons ([@B92]; [@B20]; [@B67]; [@B104]; [@B10]; [@B18]). However, the precise mechanism by which astrocytes release ATP are not well understood and both Ca^2+^-dependent exocytosis ([@B20]; [@B78]; [@B74]; [@B77]; [@B48]) and non-vesicular release pathways ([@B92]; [@B93], [@B94]; [@B53]) have been described. Lysosomes can be a relevant source of vesicular ATP release from astrocytes, with the fusion of lysosomal and plasma membranes leading to ATP exocytosis ([@B105]; [@B98]).

Vesicular nucleotide transporter is expressed in C6 glioma cells and primary cultures of cortical astrocytes, where it is mainly associated to lysosomes, as demonstrated by the co-localization of VNUT-EGFP with lysosomal markers ([@B73]). Interestingly, VNUT-associated lysosomes release their content in response to elevations of the intracellular Ca^2+^ concentration, but they do not completely collapse into the plasma membrane after lysosomal exocytosis, as VNUT remains associated with the secretory lysosome and failed to spread into the plasma membrane, suggesting that lysosomes retain their spherical structure for a long time after fusion to plasma membrane. Such "kiss and stay" mechanism is quite different from the behavior of synaptic or dense-core vesicles, which easily spread into the plasma membrane during fusion events ([@B73]). ATP uptake into the secretory lysosomes decreased by pharmacological inhibition of VNUT by Evans blue. Moreover, silencing of VNUT expression by siRNA or inhibition of VNUT function by Evans blue reduced the amount of ATP released by the cells, whereas overexpression of VNUT increased it. Collectively, these data demonstrate the implication of VNUT in ATP storage in secretory lysosomes in astrocytes and its relevant role in astrocytic ATP release by lysosomal exocytosis ([@B73]). VNUT co-localize with the lysosomal marker LAMP3 in rat optic nerve head astrocytes that release lysosomal ATP after stimulation of the toll-like receptor 3 (TLR3), which is an additional evidence supporting the role of VNUT in the storage of ATP in secretory lysosomes in astrocytes ([@B8]).

Astrocytes residing near the brainstem ventral surface (central respiratory chemosensitive area) respond to physiological reductions in pH with elevations in intracellular Ca^2+^ and ATP release. ATP stimulates the brainstem respiratory network, thus contributing to adaptive changes in lung ventilation. In terms of their sensitivity to pH, ventral brainstem astrocytes clearly differ from astrocytes that reside in other parts of the brain, such as cerebral cortex astrocytes, which indicates that these cells are functionally specialized ([@B43]). Compared to cortical astrocytes, ventral brainstem astrocytes showed increased levels of expression of genes encoding proteins associated with vesicular ATP transport and vesicular fusion, including VNUT ([@B43]), which suggests that astrocytes of the brainstem chemosensitive area are able to respond to acidification with enhanced vesicular release of ATP. Moreover, ATP released from astrocytes, possibly by the exocytosis of VNUT-possesing vesicular compartments, is involved in sensing of physiological changes in oxygen concentration in the brain ([@B5]).

ATP derived from astrocytes modulates depressive behaviors in mice ([@B16]). In this sense, VNUT-dependent ATP release from astrocytes seems to play a pivotal role in the therapeutic effect of the anti-depressant fluoxetine ([@B46]). Fluoxetine increases exocytotic ATP release in primary cultures of hippocampal astrocytes. Fluoxetine-induced ATP release was significantly reduced in astrocytes obtained from VNUT-knockdown mice, indicating that fluoxetine, at least in part, stimulates the release of ATP by VNUT-dependent exocytosis ([@B46]). Fluoxetine-induced anti-depressive behavior was decreased in VNUT-knockdown mice and, relevantly, the anti-depressive effects of fluoxetine were dependent on astrocytic VNUT, as demonstrated in mice with selective knockout or overexpression of the VNUT gene in astrocytes. A decrease or increase of VNUT in astrocytes, resulted in a decrease or increase in the anti-depressive effects induced by fluoxetine, respectively. These findings demonstrate that fluoxetine acts on astrocytes and mediates its anti-depressive effect by increasing VNUT-dependent ATP exocytosis from these cells ([@B46]). Released ATP and its metabolite adenosine act on P2Y~11~ and adenosine A2b receptors expressed by astrocytes, inducing an increase in brain-derived neurotrophic factor (BDNF), which is considered to have a relevant role in the therapeutic action of anti-depressants ([@B46]).

### VNUT in the Microglia

Microglial cells constitute the resident immune cell population of the mammalian central nervous system. These cells monitor environmental changes and act as damage sensors within the brain. Any type of injury or pathological process induces the activation of the microglia, which change their morphology, migrate to the site of injury, proliferate, produce/release several substances that affect pathological processes, or even phagocytose damaged cells or debris to restore the brain homeostasis ([@B45]). Extracellular nucleotides are relevant mediators that regulate the function of the microglia and, consequently, purinoceptor-mediated microglial responses have received much attention ([@B15]). Microglia release ATP in response to different stimuli, such as ATP or glutamate ([@B52]; [@B23]). The mechanisms involved in ATP release from microglia remain unclear, although participation of connexin 43 (Cx43) hemichannels has been described ([@B56]).

Vesicular nucleotide transporter was found to be expressed in vesicular-like structures in primary cultured microglia and exhibited no co-localization with lysosomes ([@B36]). When cells where incubated with the fluorescent ATP analog 2′/3′-O-(*N*-Methyl-anthraniloyl)-adenosine-5′-triphosphate (MANT-ATP), the existence of many ATP-possessing vesicular structures could be observed. Microglia release ATP in an exocytotic manner: when cells were stimulated with ionomycin they released ATP and such release was dependent on Ca^2+^, vesicular H^+^-ATPase and soluble *N*-ethylmaleimide sensitive factor attachment protein receptors (SNAREs), but independent on connexin/pannexin hemichannels. Additionally, exocytotic events of ATP-containing vesicles could be visualized by quinacrine-based TIRF microscopy in the microglial cell line MG5 ([@B36]). Ionomycin-induced ATP release from microglial cells was dependent upon VNUT, as release was significantly reduced when cells were treated with VNUT-siRNA. These findings demonstrated that microglia possess functional VNUT by which microglial cells store and release ATP in an exocytotic process ([@B36]). Moreover, stimulation of MG5 cells with the bacterial endotoxin lipopolysaccharide (LPS) significantly increased ionomycin-evoked ATP release, which was associated with an increase in VNUT expression. The increase in ATP release by LPS was abolished by the knockdown of VNUT (treatment of the cells with VNUT siRNA), indicating that the increase in VNUT by LPS should be responsible for the enhancement of the ATP release in microglial MG5 cells. This could be of relevance because, during infections or brain injuries, microglia could increase exocytotic ATP release by increasing VNUT ([@B36]).

Methylmercury (MeHg) is a well-known environmental pollutant that easily crosses the blood-brain barrier, inducing severe neuronal damage. It has been described that cultured microglia sense low concentrations of MeHg and release ATP in response to this neurotoxicant ([@B90]). MeHg-evoked ATP release is significantly reduced by treatment with the botulinum toxin A, a toxin that cleaves synaptosomal-associated proteins (SNAPs), thereby preventing exocytosis. Moreover, microglia cultures prepared from VNUT knockout mice showed no ATP release when exposed to MeHg, in contrast to the significant ATP release from wild-type microglia. These results indicate that MeHg stimulates the exocytic release of ATP from microglial cells via a VNUT-dependent pathway ([@B90]). The microglia-derived ATP in turn stimulates P2Y~1~ receptors in astrocytes, which induces the release of interleukin-6 (IL-6), thus protecting neurons against MeHg. These neuroprotective effects were observed in organotypic slices from the hippocampus of wild-type mice, but not in slices obtained from VNUT knockdown mice, where MeHg failed to induce ATP release or IL-6production, which resulted in neuronal damage induced by MeHg ([@B90]).

Role of VNUT in Central Nervous System Physiology and Disease
=============================================================

Role of VNUT in the Regulation of Neuronal Differentiation and Neuritogenesis
-----------------------------------------------------------------------------

Differentiation of the axon is a pivotal process that gives rise to a complex morphology and physiology of neurons. Axon formation and growth is regulated by a variety of extracellular mediators, such as neurotransmitters, neurotrophic factors and other signaling molecules. Stimulating cultured hippocampal neurons with ATP evokes Ca^2+^ transients in the distal part of the axon which exerts a negative effect on axon growth, reducing both axonal length and branching ([@B21]). This effect is mediated through P2X7 receptors that are expressed at the growth cone of the axon. Either the pharmacological inhibition of P2X7 receptor or its silencing by shRNA results in longer and more-branched axons, which is coupled to morphological changes of the growth cone ([@B21]). This effect of ATP on axonal growth was corroborated by the finding that tissue-nonspecific alkaline phosphatase (TNAP) regulates axonal elongation and branching in hippocampal neurons by controlling the local availability of growth-inhibiting extracellular ATP ([@B22]). Moreover, P2X7 receptors negatively regulate neurite formation in mouse Neuro-2a (N2a) neuroblastoma cell line ([@B26]). Pharmacological inhibition and interference of P2X7 receptor expression were associated with neuritogenesis in N2a cells, whereas P2X7 overexpression significantly reduced neurite formation. Neurotrophic effects of P2X7 were mediated through the modulation of the activity of the Ca^2+^/calmodulin-dependent kinase II and some of its downstream effectors, which have been related to axonal growth and neuronal differentiation processes ([@B26]). Thus, N2a cells have been shown to be a suitable model to analyze the sequence of purinergic events that regulate neuronal differentiation.

Although N2a cells express very small amounts of endogenous VNUT, this transporter can be successfully heterologously expressed in this cell line, and co-localization of VNUT with the vesicular marker synaptophysin could be observed by confocal microscopy imaging ([@B59]). Retinoic acid-induced differentiation keeps VNUT expression in transfected N2a cells. Functionality of the vesicular transporter was assessed by luciferin-luciferase assays to measure ionomycin-induced ATP release from differentiated N2a cells ([@B59]). Expression of VNUT clearly decreases neuritogenesis in retinoic acid-treated N2a cells, as both the number and length of neurites are reduced when compared to control (VNUT non-expressing) cells. To corroborate the VNUT negative effect on neuritogenesis, shVNUT was used to knockdown VNUT expression in VNUT-transfected and differentiated cells. These cells, where VNUT expression was reduced, showed more prominent neuritogenesis, with an increase in both the number and length of neurites. These results highlight the role of VNUT as a key component in the sequence of events involved in extracellular ATP regulation of neuritogenesis and neuronal differentiation processes ([@B59]).

VNUT in the Spinal Cord: Role of VNUT-Dependent ATP Release in Neuropathic Pain
-------------------------------------------------------------------------------

In the spinal cord, VNUT has been related to neuropathic pain, a hypersensitivity to pain that occurs after damage of a peripheral nerve as a consequence of traumatic injury or diseases such as diabetes mellitus, multiple sclerosis or cancer. Accumulating evidence indicated the crucial role of microglial cells in the spinal cord in the development of neuropathic pain. After damage of a peripheral nerve, spinal microglia turn into a reactive state through a sequence of molecular and cellular changes, which include the increase in the expression of genes that encode purinergic receptors, such as P2X4 or P2Y~12~. In response to the activation of these ATP receptors, microglial cells release different bioactive factors that cause abnormal neurotransmission in the nociceptive network in spinal dorsal horn (SDH). These pathological alterations result in pain hypersensitivity that converts initially innocuous stimuli into nociceptive signals ([@B97]; [@B96]).

Spinal dorsal horn neurons have been identified as a source of extracellular ATP that contributes to peripheral nerve injury (PNI) induced pain hypersensitivity ([@B57]). PNI increases VNUT expression in the spinal cord and this upregulation of VNUT is required for the development of tactile allodynia (abnormal pain hypersensitivity evoked by innocuous stimuli), as the intrathecal administration of siRNA targeting *VNUT* in mice subjected to PNI, significantly reduced the expression of spinal VNUT and ameliorated PNI-evoked allodynia. Moreover, PNI also increased extracellular ATP content within the spinal cord and this increase was suppressed by vesicular exocytosis inhibitors ([@B57]). VNUT-deficient (*VNUT^-/-^*) mice did not shown PNI-evoked increase in extracellular ATP concentration and had attenuated pain hypersensitivity. Attenuation of PNI-induced allodynia and reduction in spinal extracellular ATP content was also observed in mice with specific deletion of VNUT in SDH neurons, but not in mice lacking VNUT in primary sensory neurons, astrocytes or microglia. Moreover, ectopic expression of VNUT in SDH neurons of VNUT-deficient mice restored PNI-evoked increase in extracellular ATP and pain. These results showed that VNUT-dependent exocytotic ATP release from dorsal horn neurons is an essential mechanism for neuropathic pain after PNI ([@B57]).

Vesicular nucleotide transporter is expressed in subpopulations of rat dorsal root ganglion (DRG) neurons ([@B68]). In a model of rats subjected to nerve injury (L5 spinal nerve ligation), an increase in VNUT expression was observed in injured DRG neurons. Moreover, VNUT co-localize with the lysosomal protein LAMP1 in these cells ([@B42]). Fluorescent labeling of lysosomal vesicles demonstrated that ATP containing VNUT-positive lysosomes are transported to the central nerve terminals of DRG neurons in the dorsal horn. Although there is no direct evidence of ATP release from primary afferent nerve terminals in dorsal horn through lysosomal exocytosis, a previous *in vitro* study revealed exocytotic ATP release from lysosomes in primary cultured DRG neurons ([@B41]). In the light of these findings, it has been suggested that lysosomal exocytosis from central terminals of DRG neurons could be an additional source of ATP that contribute to activation of the microglia in the dorsal horn after nerve injury ([@B42]).

Vesicular nucleotide transporter shows strong similarities with other members of the family of SCL17 anion transporters, such as the vesicular glutamate transporter (VGLUT). VGLUT undergoes unusual regulation by Cl^-^. Glutamate uptake into vesicles shows biphasic dependence with the concentration of this ion: low Cl^-^ concentrations (2--8 mM) stimulate glutamate transport while high concentrations (\>20 mM) inhibit it. It has been suggested that Cl^-^ acts as an allosteric modulator of VGLUT that triggers glutamate uptake upon binding to the transporter ([@B40]), whereas the inhibition of vesicular glutamate accumulation by high Cl^-^ concentrations could be related to the dissipation of Δψ, the component of ΔμH^+^ that drives vesicular glutamate uptake. However, the precise molecular mechanism underlying the regulation of VGLUT by Cl^-^ is still to be clarified. Ketone bodies inhibit vesicular glutamate transport by competing with Cl^-^ at the site of allosteric regulation ([@B40]), which suggest a metabolic control of vesicular glutamate release. The strong dependence on transport activity with Cl^-^ concentration is a characteristic shared by other members of the SLC17 family such as VNUT. Presence of this ion is an absolute requirement for ATP transport activity in VNUT, as nucleotide transport cannot be detected in the absence of Cl^-^. Br^-^ also activates transport, whereas I^-^, F^-^, nitrate, sulfate, and thiocyanate are ineffective ([@B88]). This anion dependence is very similar to that of VGLUT2 ([@B40]). Moreover, VNUT is also inhibited by ketone bodies such as acetoacetate ([Figure 1B](#F1){ref-type="fig"}), the inhibitory effect being reversible and prevented by high concentrations of Cl^-^ ([@B40]). Although detailed kinetic studies have not been carried out, these findings suggest the existence of similar anion binding sites and regulatory mechanisms in both members of the SLC17 family of transporters, VNUT and VGLUT.

Clodronate is a first-generation bisphosphonate used in antiresorptive therapy for osteoporosis. Nevertheless, studies have proved that clodronate also has analgesic properties, although the mechanism underlying this analgesic effect was unknown. Recently, clodronate was identified as a potent and selective inhibitor of ATP vesicular storage and release ([Figure 1B](#F1){ref-type="fig"}; [@B44]). *In vitro* assays demonstrated that clodronate inhibits VNUT (IC~50~ = 15.6 nM) without affecting other vesicular neurotransmitter transporters, acting as an allosteric modulator that interacts with the Cl^-^ binding site. Clodronate shifted the Cl^-^ concentration necessary for VNUT activation toward a higher activation level, suggesting a competitive interaction. Consistent with this, clodronate modulates vesicular ATP release. Low concentrations of clodronate completely inhibited ATP release from microglia, neurons and immune cells (human monocyte cell line THP-1). *In vivo* analysis revealed that clodronate attenuates neuropathic and inflammatory pain, in addition to the accompanying inflammation, in wild type but no *VNUT^-/-^* mice, without altering basal nociception ([@B44]). These results demonstrated that clodronate exerts analgesic and anti-inflammatory actions by targeting VNUT. Noticeably, clodronate is approved for clinical use in the treatment of osteoporosis and its clinical safety in humans is well established ([@B65]). Moreover, clodronate attenuates inflammatory and neuropathic pain with stronger, faster acting, and longer lasting effects than existing drugs ([@B44]; [@B64]). Thereby, clodronate is likely to be clinically useful in the treatment of chronic neuropathic pain and could open new perspectives regarding the use of VNUT inhibitors that block vesicular ATP release as therapeutic drugs.

VNUT in the Retina: Possible Role of VNUT in the Development of Glaucoma
------------------------------------------------------------------------

Using laser microdissected retinal samples, VNUT mRNA expression was detected in photoreceptor and inner nuclear layer/ganglion cell layer (INL/GCL) samples ([@B99]). Immunochemical studies have shown that VNUT appear to be widely distributed throughout the inner and outer retinal layers, with particular strong immunoreactivity detected in the outer segments of photoreceptors, outer plexiform layer, inner plexiform layer and ganglion cell layer. Presence of VNUT in these retinal areas was confirmed by the loss of VNUT immunoreactivity in the retina from VNUT knockout (*VNUT^-/-^*) mice ([@B62]). Double-labeling immunochemistry showed that VNUT is co-localized with synaptophysin and VGLUT1 in photoreceptor cells, whereas it is co-localized with vesicular γ-aminobutyric acid (GABA) transporter (VGAT) in bipolar and amacrine cells. VNUT is also present in astrocytes and Müller cells. Retinal membrane fraction took up radiolabeled ATP in a DIDS and bafilomycin A1 (a vacuolar ATPase inhibitor) sensitive manner, this ATP-uptake activity being absent in retinal membrane vesicles prepared from *VNUT^-/-^* mice ([@B62]). Thus, these results indicate that VNUT is widely present in retina, where ATP can be stored and released to initiate purinergic chemical transmission.

Vesicular nucleotide transporter immunoreactivity can be detected in TH positive dopaminergic amacrine/interplexiform cells ([@B32]). Three-dimensional reconstruction of retinal flatmounts immunolabelled with VNUT showed that VNUT-positive amacrine/plexiform cells processes are closely associated with cone photoreceptors terminals and horizontal cells, which are known to express P2 purinergic receptors. In order to assess function, dissociated retinal neurons were loaded with fluorescent dopamine (FFN102) and ATP (MANT-ATP, quinacrine) markers and immunostained with a VNUT antibody. VNUT-immunoreactive neurons load fluorescent ATP and dopamine markers in vesicles. Moreover, ATP and dopamine markers co-localize in these cells, thus indicating co-loading of ATP and dopamine in vesicles within the VNUT-positive neurons. Fluorescence of the ATP marker quinacrine was reduced upon K^+^ stimulation, this response being blocked in the presence of cadmium. Taken together, all these results indicate that dopaminergic neurons in the retina release ATP via calcium dependent exocytosis, which may modulate the visual response by stimulating purinergic receptors in closely associated cells ([@B32]).

Retinal extracellular ATP levels and changes in VNUT expression have been analyzed in the DBA/2J mouse model of glaucoma during the development of the disease ([@B79]). For this purpose, retinas were dissected from glaucomatous animals at 3, 9, 15, and 22 months of age. C57BL/6J mice were used as age-matched controls. Retinal net ATP release increased with the progression of the pathology, varying from 0.32 pmol/retina (3 months) to 1.10 pmol/retina (15 months, threefold increase). Concomitantly, a significant increase in VNUT expression in DBA/2J mice retina during glaucoma progression was detected. These data may suggest a possible correlation between retinal dysfunction and increased levels of extracellular ATP and nucleotide transporter ([@B79]).

Concluding Remarks
==================

It is widely accepted that VNUT is responsible for the storage of ATP and other nucleotides into secretory vesicles and therefore plays an essential role in the vesicular release of nucleotides and the initiation of purinergic chemical transmission. Both the reduction in the expression of VNUT and the inhibition of its activity reduce the vesicular release of ATP and lead to a decrease in purinergic chemical signaling. VNUT appear to be widely expressed in the central nervous system, being present in neurons, astrocytes and microglial cells. Accumulating evidence indicate the involvement of VNUT-dependent nucleotide release in a diversity of biological processes in the central nervous system, which include development of the cerebellar cortex, neuronal differentiation and neuritogenesis, sensing of physiological changes in pH and brain oxygenation, protection against neurotoxicants or modulation of depressive behaviors. The expression pattern, localization and functions of VNUT in the central nervous system are summarized in [Table 1](#T1){ref-type="table"}. Deficiencies in the vesicular release of ATP could have beneficial effects in certain pathological conditions. In particular, increased levels of extracellular ATP have correlated with retinal dysfunction during the development of glaucoma. Moreover, mice deficient in VNUT show attenuated neuropathic pain, and the selective inhibitor of VNUT, clodronate, exerts analgesic effects. Therefore, VNUT could constitute a new and relevant molecular target in the context of the pathophysiology of purinergic transmission. Impairment of purinergic signaling by inhibiting the activity of VNUT or silencing VNUT gene expression may represent a new and promising therapeutical strategy for the treatment of a variety of pathological conditions.

###### 

Expression, localization, and function of VNUT in the central nervous system.

  Organ         Location (vesicle)                                                           Role                                                                 References
  ------------- ---------------------------------------------------------------------------- -------------------------------------------------------------------- ----------------
  Brain         Hippocampal neurons (synaptic vesicles, postsynaptic vesicular structures)   VNUT-dependent ATP release                                           [@B49]; [@B87]
                Cerebellar granule neurons (synaptic vesicles, lysosomes)                    Granule cell development                                             [@B60]
                Bergmann glia                                                                ND                                                                   [@B58]
                Midbrain dopaminergic neurons                                                Vesicular ATP release                                                [@B32]
                Cortical astrocytes (lysosomes)                                              Lysosomal ATP release                                                [@B73]; [@B8]
                Brainstem astrocytes                                                         Response to changes in pH and brain oxygenation                      [@B43]; [@B5]
                Hippocampal astrocytes                                                       Effect of antidepressants                                            [@B46]
                Microglia (vesicular-like structures)                                        Exocytotic ATP release. Neuroprotective response to neurotoxicants   [@B36]; [@B90]
  Spinal cord   Dorsal horn neurons                                                          Neuropathic pain                                                     [@B57]
                Dorsal root ganglion neurons (lysosomes)                                     Microglial activation in dorsal horn after nerve injury              [@B68]; [@B42]
  Retina        Photoreceptor cells, bipolar cells, astrocytes, Müller cells                 ND                                                                   [@B62]
                Amacrine cells                                                               Calcium-dependent ATP exocytosis                                     [@B32]; [@B62]
                                                                                                                                                                  

ND, not determined.
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